Background on Osimertinib Resistance Mechanisms and Unmet Needs Driving Evaluation of Novel Therapies

Opinion
Video

This segment introduces a discussion on the MARIPOSA-2 trial evaluating amivantamab plus chemotherapy or amivantamab, lazertinib and chemotherapy in EGFR-mutant NSCLC after osimertinib progression.

Recent Videos
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
2 experts in this video
2 experts in this video
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
2 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Related Content